Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
08 oct. 2024 02h35 HE
|
Boehringer Ingelheim
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on...
NATIONALLY RANKED ROSEN LAW FIRM Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
27 mai 2024 11h33 HE
|
The Rosen Law Firm PA
NEW YORK, May 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September...
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
01 avr. 2024 08h30 HE
|
Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight
25 mars 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, March 25, 2024 (GLOBE NEWSWIRE) -- Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight The rise in the number of people suffering from cirrhosis can be...
Global Human Liver Models Market to 2028: Featuring Ascendance Biotechnology, CN Bio Innovations, Cyfuse Biomedical, Emulate and Organovo Holdings Among Others
21 févr. 2023 13h03 HE
|
Research and Markets
Dublin, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The "Human Liver Models - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Human Liver...
Non-Alcoholic Steatohepatitis (NASH) Market Worth $24.26Bn, Globally, by 2028 at 47.1% CAGR - Exclusive Report by The Insight Partners
04 mai 2022 08h37 HE
|
The Insight Partners
New York, May 04, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Non-Alcoholic Steatohepatitis (NASH) Market Forecast to 2028 - COVID-19 Impact and Global Analysis...
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
18 oct. 2021 16h00 HE
|
INVENTIVA
Quatre présentations par poster confirment les effets bénéfiques de lanifibranor sur des composants clés de la NASH faisant suite à des analyses supplémentaires réalisées sur les résultats de l'étude...
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
18 oct. 2021 16h00 HE
|
INVENTIVA
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial...
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
22 mars 2021 16h01 HE
|
Akero Therapeutics
-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution -- --...
Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients
22 mars 2021 06h30 HE
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for...